Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | OGA | O60502 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16472287 | 0.82 | GPR119 (0.43) | GPR119DHFR | |
| SCHEMBL18231706 | 0.81 | GPR119 (0.42) | GPR119KCNH2DHFRHTR3AJAK2 | |
| SCHEMBL16472412 | 0.81 | GPR119 (0.42) | GPR119KCNH2DHFRHTR3AJAK2 | |
| SCHEMBL16587772 | 0.79 | AR (0.35) | GPR119KCNH2JAK2JAK1TYK2 | |
| SCHEMBL16472305 | 0.78 | GPR119 (0.40) | GPR119KCNH2HTR3AJAK2JAK1 | |
| SCHEMBL16587751 | 0.78 | GPR119 (0.42) | GPR119KCNH2DHFRJAK2JAK1 | |
| SCHEMBL16472271 | 0.78 | GPR119 (0.42) | GPR119KCNH2DHFRJAK2JAK1 | |
| SCHEMBL16472278 | 0.76 | GPR119 (0.44) | GPR119 | |
| SCHEMBL16587775 | 0.72 | OGA (0.33) | JAK2JAK1TYK2JAK3OGA | |
| SCHEMBL16472243 | 0.70 | GRIN2D (0.40) | GPR119DHFROGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987268-B2 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-24 | — | — | US | disclosed |